Autologous Anti-BCMA CAR T-cells spCART-269 - CISMeF
Autologous Anti-BCMA CAR T-cells spCART-269NCIt concept
Preferred Label : Autologous Anti-BCMA CAR T-cells spCART-269;
NCIt synonyms : Autologous Anti-BCMA CAR-T Cells spCART-269; CD269-targeted CAR T Cells;
NCIt definition : A preparation of autologous T-lymphocytes that have been genetically engineered to
express a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen
(TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily
member 17; TNFRSF17; CD269), with potential immunostimulating and antineoplastic activities.
Upon administration, the autologous anti-BCMA CAR T-cells spCART-269 recognize and
induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific
antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell
activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily
(TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces
of plasma cells and is overexpressed on malignant plasma cells.;